Patents by Inventor Gregory R. Reyes

Gregory R. Reyes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis E virus vaccine and method
    Patent number: 5741490
    Abstract: Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes a peptide corresponding to a carboxyl terminal end region of the capsid protein encoded by the second open reading frame 2 of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: April 21, 1998
    Assignee: Genelabs Technologies, Inc.
    Inventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice D. Yarbough
  • Hepatitis E virus peptides and methods
    Patent number: 5686239
    Abstract: Peptide antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV derived peptides and in particular, SG3, are immunoreactive with sera from individuals infected with HEV. The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: November 11, 1997
    Assignee: Genelabs Technologies, Inc.
    Inventors: Gregory R. Reyes, Albert W. Tam, Patrice O. Yarbough
  • HTLV-I peptide antigens and kit
    Patent number: 5614366
    Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: March 25, 1997
    Assignee: Genelabs Technologies, Inc.
    Inventors: Gregory R. Reyes, Kenneth G. Hadlock
  • Hepatitis C virus epitopes
    Patent number: 5443965
    Abstract: Peptide antigens which are immunoreactive with sera from individuals infected with hepatitis C virus (HCV) are disclosed. Several of the antigens are immunologically reactive with antibodies present in individuals identified as having chronic and acute HCV infection. The antigens are useful in diagnostic methods for detecting HCV infection in humans. Also disclosed are corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic peptides.
    Type: Grant
    Filed: April 5, 1991
    Date of Patent: August 22, 1995
    Assignee: Genelabs Incorporated
    Inventors: Gregory R. Reyes, Jungsuh P. Kim, Randolph Moeckli
  • Post-transfusion, non-A, non-B hepatitis virus polynucleotides
    Patent number: 5218099
    Abstract: Purified virus particles, antigens, antibodies reactive with viral antigens, and a viral genetic material associated with non-A, non-B hepatitis are provided by the present invention. Cloned genetic material useful both in identifying intact virus particles of the invention and for use in diagnostic techniques and/or production of antigens is also disclosed.
    Type: Grant
    Filed: June 28, 1989
    Date of Patent: June 8, 1993
    Assignees: The United States of America as represented by the Department of Health and Human Services, Genelabs Incorporated
    Inventors: Gregory R. Reyes, Daniel W. Bradley, Linda Rabin, Kirk Fry
  • Method and kit for detecting human retrovirus
    Patent number: 5169753
    Abstract: A novel retrovirus isolated from human lymphoma cells is disclosed. The retrovirus is characterized by a C-type retroviral particle of approximately 100 nm diameter; and an approximately 27,000 molecular weight p24 core protein. Also disclosed are cell lines from which the virus can be obtained and screening methods for detecting the presence of the virus in human sera.
    Type: Grant
    Filed: January 2, 1992
    Date of Patent: December 8, 1992
    Assignees: Genelabs Incorporated, The University of California
    Inventors: Valerie L. Ng, Michael S. McGrath, Gregory R. Reyes
  • Retrovirus isolated from human lymphoma cell lines
    Patent number: 5108920
    Abstract: A novel retrovirus isolated from human lymphoma cells is disclosed. The retrovirus is characterized by a C-type retroviral particle of approximately 100 nm diameter; and an approximately 27,000 molecular weight p24 core protein. Also disclosed are cell lines from which the virus can be obtained and screening methods for detecting the presence of the virus in human sera.
    Type: Grant
    Filed: June 5, 1989
    Date of Patent: April 28, 1992
    Assignees: Regents of the University of California, Genelabs Incorporated
    Inventors: Valerie L. Ng, Michael S. McGrath, Gregory R. Reyes
  • HTLV-I peptide antigen and assay
    Patent number: 5066579
    Abstract: A recombinant peptide antigen is provided which is derived from HTLV-I envelope protein gp46 and immunoreactive with anti-HTLV-I antibody present in a individuals with HTLV-I related T-cell leukemia. The antigen is useful as a diagnostic tool in determining whether an individual has been or is infected with HTLV-I, and is also useful in a method of immunizing individuals against such infection.
    Type: Grant
    Filed: June 13, 1989
    Date of Patent: November 19, 1991
    Assignee: Genelabs Incorporated
    Inventor: Gregory R. Reyes